Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Total Liabilities (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Total Liabilities readings, the most recent being $21.2 million for Q1 2026.

  • Quarterly Total Liabilities fell 8.28% to $21.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $21.2 million through Mar 2026, down 8.28% year-over-year, with the annual reading at $24.5 million for FY2025, 20.93% down from the prior year.
  • Total Liabilities hit $21.2 million in Q1 2026 for Oric Pharmaceuticals, down from $24.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $31.0 million in Q4 2024 and bottomed at $21.2 million in Q1 2026.
  • Average Total Liabilities over 5 years is $24.6 million, with a median of $23.8 million recorded in 2023.
  • The largest annual shift saw Total Liabilities surged 178.8% in 2022 before it decreased 20.93% in 2025.
  • Oric Pharmaceuticals' Total Liabilities stood at $24.8 million in 2022, then increased by 12.45% to $27.9 million in 2023, then grew by 11.11% to $31.0 million in 2024, then decreased by 20.93% to $24.5 million in 2025, then decreased by 13.55% to $21.2 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Total Liabilities are $21.2 million (Q1 2026), $24.5 million (Q4 2025), and $24.3 million (Q3 2025).